https://www.selleckchem.com/products/rp-6306.html
istered 13 December 2010; DESIR ClinicalTrials.gov identifier NCT01648907 , Registered 24 July 2012. EMBARK ClinicalTrials.gov identifier NCT01258738 , Registered 13 December 2010; DESIR ClinicalTrials.gov identifier NCT01648907 , Registered 24 July 2012. Acute respiratory distress syndrome (ARDS) is a fatal complication of coronavirus disease 2019 (COVID-19). There are a few reports of allogeneic human mesenchymal stem cells (MSCs) as a potential treatment for ARDS. In this phase 1 clinical trial, we present the safety, feasibility, an
Like
Comment
Share
